Toward the next generation of NK cell-based adoptive cancer immunotherapy

The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Miller, Matthias, Stojanovic, Ana, Cerwenka, Adelheid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654599/
https://www.ncbi.nlm.nih.gov/pubmed/23734329
http://dx.doi.org/10.4161/onci.23811
Descripción
Sumario:The adoptive transfer of interleukin (IL)-2-expanded natural killer (NK) cells has provided unsatisfactory clinical benefits to patients affected by solid tumors. Our study demonstrates that the activation of NK cells with IL-12/IL-15/IL-18 prior to transfer into tumor-bearing mice is critical for obtaining high recovery rates, effector functions in vivo and tumor regression.